NASDAQ:IVVD Invivyd (IVVD) Stock Price, News & Analysis → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free IVVD Stock Alerts $1.84 +0.03 (+1.66%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$1.80▼$1.9150-Day Range$1.68▼$4.4452-Week Range$0.98▼$5.20Volume679,440 shsAverage Volume422,601 shsMarket Capitalization$219.55 millionP/E RatioN/ADividend YieldN/APrice Target$11.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Invivyd alerts: Email Address Invivyd MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside515.9% Upside$11.33 Price TargetShort InterestBearish9.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 8 Articles This WeekInsider TradingSelling Shares$186,552 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.60) to $0.21 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.91 out of 5 starsMedical Sector662nd out of 928 stocksBiological Products, Except Diagnostic Industry110th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingInvivyd has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInvivyd has only been the subject of 3 research reports in the past 90 days.Read more about Invivyd's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.17% of the float of Invivyd has been sold short.Short Interest Ratio / Days to CoverInvivyd has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Invivyd has recently increased by 4.38%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInvivyd does not currently pay a dividend.Dividend GrowthInvivyd does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IVVD. Previous Next 1.8 News and Social Media Coverage News SentimentInvivyd has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Invivyd this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Invivyd to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Invivyd insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $186,552.00 in company stock.Percentage Held by Insiders17.90% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.36% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Invivyd's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Invivyd are expected to grow in the coming year, from ($0.60) to $0.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invivyd is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invivyd is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvivyd has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Invivyd's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About Invivyd Stock (NASDAQ:IVVD)Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Read More IVVD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IVVD Stock News HeadlinesJune 1 at 9:22 AM | insidertrades.comInvivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire Sells 112,381 SharesMay 31 at 7:05 AM | globenewswire.comInvivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal AntibodiesMay 31 at 7:00 AM | globenewswire.comInvivyd Announces the Appointment of Timothy Lee as Chief Commercial OfficerMay 29, 2024 | globenewswire.comInvivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)May 26, 2024 | americanbankingnews.comInvivyd (NASDAQ:IVVD) Earns "Buy" Rating from HC WainwrightMay 22, 2024 | globenewswire.comInvivyd Elects Two New Independent Members to its Board of DirectorsMay 14, 2024 | markets.businessinsider.comStrong Buy Rating for Invivyd Amidst Potential EUA Approval and Promising Revenue ProjectionsMay 13, 2024 | msn.comInvivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call TranscriptMay 13, 2024 | globenewswire.comInvivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 12, 2024 | finance.yahoo.comWith 31% stake, Invivyd, Inc. (NASDAQ:IVVD) seems to have captured institutional investors' interestMay 10, 2024 | finance.yahoo.comInvivyd Inc (IVVD) Reports Q1 2024 Financial Results: A Detailed AnalysisMay 9, 2024 | investorplace.comIVVD Stock Earnings: Invivyd Meets EPS for Q1 2024May 9, 2024 | globenewswire.comInvivyd Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 7, 2024 | globenewswire.comInvivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA FeedbackMay 2, 2024 | globenewswire.comInvivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business HighlightsApril 30, 2024 | globenewswire.comInvivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash PositionApril 20, 2024 | morningstar.comInvivyd Inc Ordinary SharesApril 15, 2024 | globenewswire.comInvivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™April 15, 2024 | globenewswire.comInvivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™April 12, 2024 | msn.comInvivyd appoints Jeremy Gowler as interim CEOApril 12, 2024 | markets.businessinsider.comInvivyd Appoints Jeremy Gowler As Interim CEO As Dave Hering ResignsApril 12, 2024 | globenewswire.comInvivyd Announces CEO TransitionApril 8, 2024 | ca.news.yahoo.comCanadian farmers demand relief from price on carbon imposed by federal governmentApril 5, 2024 | finanznachrichten.deInvivyd Provides PEMGARDA Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 MillionApril 4, 2024 | finance.yahoo.comInvivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 MillionSee More Headlines Receive IVVD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/02/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IVVD CUSIPN/A CIK1832038 Webadagiotx.com Phone781-819-0080FaxN/AEmployees94Year FoundedN/APrice Target and Rating Average Stock Price Target$11.33 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+515.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-198,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-93.58% Return on Assets-79.93% Debt Debt-to-Equity RatioN/A Current Ratio5.77 Quick Ratio5.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.50 per share Price / Book1.23Miscellaneous Outstanding Shares119,320,000Free Float97,958,000Market Cap$219.55 million OptionableOptionable Beta0.89 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Robert D. Allen Ph.D. (Age 55)Chief Scientific Officer Comp: $828.18kMs. Jill Andersen J.D. (Age 51)Chief Legal Officer & Corporate Secretary Comp: $931.68kMr. Jeremy Gowler (Age 47)Interim CEO, COO & Chief Commercial Officer Mr. William E. Duke Jr. (Age 52)M.B.A., Chief Financial Officer Ms. Stacy Price M.S. (Age 55)Chief Technology & Manufacturing Officer Scott YoungSenior Vice President of Investor Relations & Corporate CommunicationsMs. Julie Green M.B.A. (Age 49)Chief Human Resources Officer Ms. Heidi Spurling M.S.VP of Strategy & Operations and Chief of Staff to the CEODr. Mark A. Wingertzahn Ph.D. (Age 53)Senior Vice President of Clinical Development & Medical Affairs More ExecutivesKey CompetitorsMonte Rosa TherapeuticsNASDAQ:GLUESeres TherapeuticsNASDAQ:MCRBKinnate BiopharmaNASDAQ:KNTEbluebird bioNASDAQ:BLUEKronos BioNASDAQ:KRONView All CompetitorsInsiders & InstitutionsTerrance McguireSold 112,381 sharesTotal: $186,552.46 ($1.66/share)Tidal Investments LLCBought 28,337 shares on 5/17/2024Ownership: 0.024%Bain Capital Life Sciences Investors LLCSold 137,612 shares on 5/16/2024Ownership: 1.508%Jacobs Levy Equity Management Inc.Bought 77,603 shares on 5/16/2024Ownership: 0.365%Vanguard Group Inc.Bought 97,496 shares on 5/10/2024Ownership: 2.190%View All Insider TransactionsView All Institutional Transactions IVVD Stock Analysis - Frequently Asked Questions Should I buy or sell Invivyd stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Invivyd in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IVVD shares. View IVVD analyst ratings or view top-rated stocks. What is Invivyd's stock price target for 2024? 3 analysts have issued 1-year price targets for Invivyd's stock. Their IVVD share price targets range from $9.00 to $15.00. On average, they anticipate the company's stock price to reach $11.33 in the next twelve months. This suggests a possible upside of 515.9% from the stock's current price. View analysts price targets for IVVD or view top-rated stocks among Wall Street analysts. How have IVVD shares performed in 2024? Invivyd's stock was trading at $3.94 at the beginning of the year. Since then, IVVD stock has decreased by 53.3% and is now trading at $1.84. View the best growth stocks for 2024 here. When is Invivyd's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our IVVD earnings forecast. How were Invivyd's earnings last quarter? Invivyd, Inc. (NASDAQ:IVVD) posted its earnings results on Thursday, May, 9th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.13. What ETF holds Invivyd's stock? Amplify Treatments, Testing and Advancements ETF holds 26,041 shares of IVVD stock, representing 0.47% of its portfolio. Who are Invivyd's major shareholders? Invivyd's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.19%), Bain Capital Life Sciences Investors LLC (1.51%), Jacobs Levy Equity Management Inc. (0.36%), Acadian Asset Management LLC (0.17%), Chase Investment Counsel Corp (0.05%) and Tidal Investments LLC (0.02%). Insiders that own company stock include Adimab, Llc and Terrance Mcguire. View institutional ownership trends. How do I buy shares of Invivyd? Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IVVD) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
